您的位置: 首页 > 2019年3月 第50卷 第2期 > 文字全文
2023年7月 第38卷 第7期11
目录

炎症性肠病活动程度与血脂水平的相关性分析

Clinical analysis of the correlations between disease activity of inflammatory bowel disease and lipid profiles

来源期刊: 广州医药 | 24-27 发布时间:2021-12-17 收稿时间:2025/11/13 17:32:45 阅读量:138
作者:
关键词:
炎症性肠病疾病活动程度血脂
Inflammatory bowel diseaseDisease activityLipid profiles
DOI:
10.3969/j.issn.1000-8535.2019.02.006
收稿时间:
2018-12-04 
修订日期:
 
接收日期:
 
引用总数:
0  
目的 通过比较炎症性肠病(IBD)患者的血脂水平,探讨炎症性肠病疾病活动程度与血脂的相关性。方法 收集2013年1月—2018年5月在南方医科大学附属南海医院住院的159例IBD患者和159例健康对照为研究对象,检测分析两组的血浆TG、TC、LDL-C、HDL-C、脂蛋白a、白蛋白和超敏C反应蛋白(hCRP)水平差异,分析IBD患者疾病活动程度与血脂异常的关系。结果 与对照组比较,IBD患者的TG、TC、LDL-C、HDL-C和白蛋白均下降,但脂蛋白a升高(P<0.05),且CD组的TC、LDL-C、HDL-C、白蛋白均较UC组更低(P<0.05)。TC、LDL-C、HDL-C等胆固醇水平随IBD疾病活动程度加重而逐渐下降,且与hCPR呈负相关,脂蛋白a与hCRP呈正相关性,但未见TG水平与疾病活动相关。结论 IBD患者的胆固醇水平下降,脂蛋白a升高,CD患者更明显,胆固醇水平随IBD病情加重逐渐下降,且与hCRP呈负相关。
Objective To explore the correlations between disease activity of inflammatory bowel disease(IBD) and lipid profiles levels by compare the levels of plasma lipids in patients with IBD. Methods A total of 159 IBD patients admitted to Nanhai Hospital of Southern Medical University from January 2013 to May 2018 were included in the study and the clinical data were collected. There were 159 healthy people recruited in the control group. The differences of plasma levels of triglycerides(TG), total cholesterol(TC), low-density lipoprotein cholesterol(LDL-C), high-density lipoprotein cholesterol(HDL-C), lipoprotein(a), albumin and high-sensitivity C-reactive protein(hCRP) between these two groups were analyzed respectively. The relationships between lipids levels and the severity of IBD were analyzed. Results Plasma levels of TG,TC,LDL-C,HDL-C and albumin were lower in IBD group than those in control group,but lipoprotein(a) was higher than control group(P<0.05). The levels of TC,LDL-C,HDL-C and albumin were lower in CD patients compared to those of UC(P<0.05). Plasma levels of TC,LDL-C,HDL-C gradually decreased with the severity of IBD. TC,LDL-C,HDL-C values were negatively correlated with hCRP levels in IBD patients. And lipoprotein(a) values was positively correlated with hCRP levels in IBD patient. However, there was no association between TG levels and the severity of IBD. Conclusion TG、TC、LDL-C、HDL-C levels are decreased and lipoprotein(a) is increased in IBD patients, especially CD patients, compared with healthy controls. Moreover, the cholesterol levels are negatively associated with more severe disease activity.
1、 ZeWINGER S, KLEBER M E, TRAGANTE V, et al. Relations between lipoprotein(a) concentrations, LPA genetic variants, and the risk of mortality in patients with established coronary heart disease: a molecular and genetic association study[J]. Lancet Diabetes Endocrinol, 2017,5(7):534-543. ZeWINGER S, KLEBER M E, TRAGANTE V, et al. Relations between lipoprotein(a) concentrations, LPA genetic variants, and the risk of mortality in patients with established coronary heart disease: a molecular and genetic association study[J]. Lancet Diabetes Endocrinol, 2017,5(7):534-543.
2、 KONTUSH A. HDL-mediated mechanisms of protection in cardiovascular disease[J]. Cardiovasc Res, 2014,103(3):341-349. KONTUSH A. HDL-mediated mechanisms of protection in cardiovascular disease[J]. Cardiovasc Res, 2014,103(3):341-349.
3、 KOHAN A B. Apolipoprotein C-III: a potent modulator of hypertriglyceridemia and cardiovascular disease[J]. Curr Opin Endocrinol Diabetes Obes, 2015,22(2):119-125. KOHAN A B. Apolipoprotein C-III: a potent modulator of hypertriglyceridemia and cardiovascular disease[J]. Curr Opin Endocrinol Diabetes Obes, 2015,22(2):119-125.
4、 张雷, 鞠大闯, 刘庭惠, 等. 复方纳米银抗菌水凝胶对溃疡性结肠炎大鼠肠道屏障功能的影响[J]. 现代医院, 2016,16(5):644-646, 649. 张雷, 鞠大闯, 刘庭惠, 等. 复方纳米银抗菌水凝胶对溃疡性结肠炎大鼠肠道屏障功能的影响[J]. 现代医院, 2016,16(5):644-646, 649.
5、 潘丹峰, 苍玉珍. 应用膳食平衡指数评价溃疡性结肠炎患者膳食质量及营养状况[J]. 广州医药, 2018,49(4):34-38. 潘丹峰, 苍玉珍. 应用膳食平衡指数评价溃疡性结肠炎患者膳食质量及营养状况[J]. 广州医药, 2018,49(4):34-38.
6、 中国炎症性肠病协作组, 王玉芳, 欧阳钦. 3100例溃疡性结肠炎住院病例回顾分析[J]. 中华消化杂志, 2006,26 (6):368-372. 中国炎症性肠病协作组, 王玉芳, 欧阳钦. 3100例溃疡性结肠炎住院病例回顾分析[J]. 中华消化杂志, 2006,26 (6):368-372.
7、 张俊清. 探寻东西方2型糖尿病的差异——从现象到本质的思考[J]. 中国糖尿病杂志, 2016,24 (10):955-960. 张俊清. 探寻东西方2型糖尿病的差异——从现象到本质的思考[J]. 中国糖尿病杂志, 2016,24 (10):955-960.
8、 BECKER S A, MCCLAVE S A. Lipid profiles in Crohn's disease patients with and without ileal resection[J]. Am J Gastroenterol, 1996,91(11):2452. BECKER S A, MCCLAVE S A. Lipid profiles in Crohn's disease patients with and without ileal resection[J]. Am J Gastroenterol, 1996,91(11):2452.
9、 BORBA E F, CARVALHO J F, BONFA E. Mechanisms of dyslipoproteinemias in systemic lupus erythematosus[J]. Clin Dev Immunol, 2006,13(2-4):203-208. BORBA E F, CARVALHO J F, BONFA E. Mechanisms of dyslipoproteinemias in systemic lupus erythematosus[J]. Clin Dev Immunol, 2006,13(2-4):203-208.
10、 ZENG Z, ZHU Z, YANG Y, et al. Incidence and clinical characteristics of inflammatory bowel disease in a developed region of Guangdong province, China: a prospective population-based study[J]. J Gastroenterol Hepatol, 2013,28(7):1148-1153. ZENG Z, ZHU Z, YANG Y, et al. Incidence and clinical characteristics of inflammatory bowel disease in a developed region of Guangdong province, China: a prospective population-based study[J]. J Gastroenterol Hepatol, 2013,28(7):1148-1153.
11、 贾喻, 王娟, 刘醒醒, 等. 溃疡性结肠炎患者的血脂异常及其临床意义[J]. 江苏医药, 2016,42 (11):1241-1243. 贾喻, 王娟, 刘醒醒, 等. 溃疡性结肠炎患者的血脂异常及其临床意义[J]. 江苏医药, 2016,42 (11):1241-1243.
12、 KOUTROUMPAKIS E, RAMOS-RIVERS C, REGUEIRO M, et al. Association between long-term lipid profiles and disease severity in a large cohort of patients with inflammatory bowel disease[J]. Dig Dis Sci, 2016,61(3):865-871. KOUTROUMPAKIS E, RAMOS-RIVERS C, REGUEIRO M, et al. Association between long-term lipid profiles and disease severity in a large cohort of patients with inflammatory bowel disease[J]. Dig Dis Sci, 2016,61(3):865-871.
13、 ROMANATO G, SCARPA M, ANGRIMAN I, et al. Plasma lipids and inflammation in active inflammatory bowel diseases[J]. Aliment Pharmacol Ther, 2009,29(3):298-307. ROMANATO G, SCARPA M, ANGRIMAN I, et al. Plasma lipids and inflammation in active inflammatory bowel diseases[J]. Aliment Pharmacol Ther, 2009,29(3):298-307.
14、 SAPPATI B R, PUTKA B S, MULLEN K D. Dyslipidemia and lipoprotein profiles in patients with inflammatory bowel disease[J]. J Clin Lipidol, 2010,4(6):478-482. SAPPATI B R, PUTKA B S, MULLEN K D. Dyslipidemia and lipoprotein profiles in patients with inflammatory bowel disease[J]. J Clin Lipidol, 2010,4(6):478-482.
15、 LIBBY P. Inflammation in atherosclerosis[J]. Nature, 2002,420(6917):868-874. LIBBY P. Inflammation in atherosclerosis[J]. Nature, 2002,420(6917):868-874.
16、 RUNGOE C, BASIT S, RANTHE M F, et al. Risk of ischaemic heart disease in patients with inflammatory bowel disease: a nationwide Danish cohort study[J]. Gut, 2013,62(5):689-694. RUNGOE C, BASIT S, RANTHE M F, et al. Risk of ischaemic heart disease in patients with inflammatory bowel disease: a nationwide Danish cohort study[J]. Gut, 2013,62(5):689-694.
17、 中华医学会消化病学分会炎症性肠病学组. 炎症性肠病诊断与治疗的共识意见(2018 年,北京)[J]. 中华消化杂志, 2018,38(5):292-311. 中华医学会消化病学分会炎症性肠病学组. 炎症性肠病诊断与治疗的共识意见(2018 年,北京)[J]. 中华消化杂志, 2018,38(5):292-311.
18、 KAPLAN G G, NG S C. Understanding and preventing the global increase of inflammatory bowel disease[J]. Gastroenterol, 2017,152(2):313-321. KAPLAN G G, NG S C. Understanding and preventing the global increase of inflammatory bowel disease[J]. Gastroenterol, 2017,152(2):313-321.
上一篇
下一篇
出版者信息








《广州医药》公众号
目录